Full text is available at the source.
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide ‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease
How previous diabetes treatments affect kidney and heart results of combined SGLT2 inhibitor and GLP-1 receptor agonist therapy in type 2 diabetes with chronic kidney disease
AI simplified
Abstract
In a study of 438 patients with chronic kidney disease and type 2 diabetes, the incidence of renal composite outcomes was 10% for those receiving GLP-1 receptor agonist first and 17% for those receiving SGLT2 inhibitor first.
- The composite renal outcome included progression to macroalbuminuria and/or a ≥50% decrease in estimated glomerular filtration rate.
- No significant difference in the incidence of renal outcomes was found between the GLP-1RA-first group and the SGLT2 inhibitor-first group.
- The odds ratio for the incidence of renal outcomes was 1.80, suggesting a higher occurrence in the SGLT2 inhibitor-first group, but this was not statistically significant.
- The win ratio indicated a significant advantage for the GLP-1RA-first group, with a win ratio of 1.83, highlighting more favorable renal outcomes.
- These findings may suggest that initiating therapy with GLP-1RA could be associated with better renal outcomes when combined with SGLT2 inhibitors.
AI simplified